INDO Doo'd DAYMEN 19 IAM SOME

P29138.P01.doc	IAPS RECTOPUTATION A SI JAIN ZUUD							
Form PTO-1390	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							
TRANSMITTAL LETTER TO DESIGNATED/ELECTED CONCERNING A FILING	OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/564407						
INTERNATIONAL APPLICATION NO. PCT/JP2004/010558	INTERNATIONAL FILING DATE July 16, 2004	PRIORITY DATE CLAIMED July 16, 2003						
TITLE OF INVENTION MEDICAMENT FOR TREATMENT OF DERMAL PIGMENTATION								
APPLICANT(S) FOR DO/EO/US Akiko ITAI and Susumu MUTO								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.								
1. Main This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3. A This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below.								
4. The US has been elected (PCT Article 31).								
 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 								
 a. is attached hereto. 	 ✓ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). a. ⋈ is attached hereto. b. ☐ has been previously submitted under 35 U.S.C. 154 (d) (4). 							
 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 								
8.	8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35 U.S.C371(c)(4)).								
"UNEXECUTED"								
10. An English language translation of (35 U.S.C. 371(c)(5)).	0. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11 to 22 below concern other document(s) or information included:								
11. Assignee: INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. of Tokyo, Japan								
12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
14. ☒ A FIRST preliminary amendment. ☐ A SECOND or SUBSEQUENT pr	☑ A FIRST preliminary amendment.☐ A SECOND or SUBSEQUENT preliminary amendment.							
15.	☐ An Application Data Sheet under 37 C.F.R. 1.76.							
16. A substitute specification.	☐ A substitute specification.							
17. A power of attorney and/or change	A power of attorney and/or change of address letter.							
18. Figure of Drawing to be published	Figure of Drawing to be published:							
19. A computer-readable form of the	omputer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.							
20. A second copy of the published in	A second copy of the published international application under 35 U.S.C. 154 (d) (4).							
21. A second copy of the English land (d) (4).	21. A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4).							
PCT/ISA/210-Internatioanal Sear	tion as published in Japanese tion as filed in Japanese could be considered to Report in Japanese; PCT/ISA/237 in panese; PCT/IB/301; PCT/IB/304; PCT	in Japanese; 7/IB/308; PCT/IB/332;						

U.S. APPLICATION NO. (If known, see 37		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER			
CFR 1.5) Not Yet A	2044U/	PCT/JP2004/	010558	P29	0138		
				CALCULATIONS	PTO USE ONLY		
23 🖾 The following fees are submitted: Basic national fee				\$ 300.00			
24 🖾 Examination Fee	and experimental report	\$ 200.00					
If International prelimina provisions of PCT Article All other situations							
25 Search fee		\$ 400.00					
Search fee (37 CFR 1.44 an International Search Rep	g Authority						
	·····						
TOTAL 23, 24 and 25 =				\$ 900.00			
Additional Fee for Specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in electronic medium). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE				
116 -100=	16 /50 =	1	× \$250.00	\$ 250.00			
		or declaration later than					
	1	ate (37 CFR 1.492(h)).			ļ		
Claims	Number Filed	Number Extra	Rate	* • • • • • • • • • • • • • • • • • • •	ļ		
Total Claims	13 - 20 =	0	x \$50.00	\$ 0.00			
Independent Claims			x \$200.00	\$ 0.00			
Multiple Dependent Cl	aim(s) (ii applicable)	TOTAL OF ABOVE CO	+ \$360.00	\$ 0.00			
TOTAL OF ABOVE CALCULATIONS = Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.				\$1,150.00 \$ 0.00			
SUBTOTAL =				\$1,150.00			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492 (i)).				\$ 0.00			
Extension of Time fee in the amount of \$				\$ 0.00	<u> </u>		
TOTAL NATIONAL FEE =				\$1,150.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00			
TOTAL FEES ENCLOSED =				\$1,150.00			
				Amount to be	\$		
		refunded					
a MA shock in the or	mount of \$ 1 150 00 to	included	Charged				
a. 🖾 A check in the amount of \$1,150.00 to cover the above fees is included.							
b. Please charge my Deposit Account Noin the amount of \$ to cover the above fees.							
c. 🗵 The U.S. Patent and Trademark Office is hereby authorized to charge any additional fees which may be required, or credit							
any overpayment to Deposit Account No. 19-0089. d. ☐ Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit car information and authorization on PTO-							
2038. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status							
SEND ALL CORRESPONDENCE TO CUSTOMER NO. 07055							
AT THE PRESENT ADDRESS OF: Arnold Turk							
Bruce H. Bernstein CREENBLIM & REPNISTEIN BLC							
GREENBLUM & BERNSTEIN, P.L.C. Bruc					ein		
1950 Roland Clark Pla Reston, VA 20191	ce	•		NAME			
(703) 716-1191				29,027			
1				REGISTRATION	INUMBER		

10/564407 IAP15 Rec'd PCT/PTO 13 JAN 2006

P29138.P02.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Akiko ITAI et al.

Mail Stop PCT

Appl. No: Not Yet Assigned

(U.S. National Phase of PCT/JP2004/010558)

I.A.Filed: July 16, 2004

For

MEDICAMENT FOR TREATMENT OF DERMAL PIGMENTATION

COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT APPLICATION FILED UNDER 35 U.S.C. 371 AND 37 C.F.R. 1.495

Mail Stop PCT

Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window, Mail Stop PCT Randolph Building **401 Dulany Street** Alexandria, VA 22314

Sir:

Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney, will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to the above, this application should be associated with Customer Number 07055, which includes the present correspondence address as follows:

> GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191

> > 1

P29138.P02.doc

If there are any questions pertaining to this National Stage Application, please contact the undersigned.

Respectfully submitted, Akiko ITAI et al.

Bruce H. Bernstein

Reg. No. 29,027

January 13, 2006 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191

Arnold Turk Reg. No. 33094